Comparative	O
immunohistochemical	O
study	O
of	O
primary	B-Cancer
and	O
metastatic	B-Cancer
carcinomas	I-Cancer
of	O
the	O
liver	B-Organ
.	O

Distinguishing	O
primary	B-Cancer
hepatocellular	I-Cancer
carcinoma	I-Cancer
(	O
HCC	B-Cancer
)	O
from	O
metastatic	B-Cancer
carcinomas	I-Cancer
to	O
the	O
liver	B-Organ
is	O
often	O
difficult	O
,	O
if	O
not	O
impossible	O
,	O
particularly	O
in	O
needle	O
biopsy	B-Multi-tissue_structure
and	O
fine	O
-	O
needle	O
aspiration	O
specimens	B-Multi-tissue_structure
.	O

In	O
an	O
attempt	O
to	O
identify	O
a	O
specific	O
immunohistochemical	O
profile	O
that	O
would	O
distinguish	O
HCC	B-Cancer
from	O
metastatic	B-Cancer
carcinomas	I-Cancer
,	O
we	O
studied	O
56	O
HCCs	B-Cancer
,	O
8	O
cholangiocarcinomas	B-Cancer
,	O
and	O
24	O
metastatic	B-Cancer
adenocarcinomas	I-Cancer
with	O
monoclonal	O
antibodies	O
to	O
alpha	O
-	O
fetoprotein	O
(	O
AFP	O
)	O
,	O
keratin	O
(	O
AE1	O
,	O
AE3	O
,	O
and	O
CAM5	O
.	O
2	O
)	O
,	O
Leu	O
-	O
M1	O
,	O
human	O
milk	O
fat	O
globule	O
(	O
HMFG	O
-	O
2	O
)	O
,	O
tumor	B-Cancer
-	O
associated	O
glycoprotein	O
-	O
72	O
(	O
B72	O
.	O
3	O
)	O
,	O
epithelial	B-Tissue
specific	O
membrane	B-Cellular_component
antigen	O
(	O
Ber	O
-	O
EP4	O
)	O
,	O
and	O
BCA	O
-	O
225	O
(	O
CU	O
-	O
18	O
)	O
.	O

Both	O
monoclonal	O
and	O
polyclonal	O
(	O
mCEA	O
and	O
pCEA	O
)	O
antibodies	O
to	O
carcinoembryonic	O
antigen	O
also	O
were	O
used	O
.	O

Metastatic	B-Cancer
adenocarcinomas	I-Cancer
were	O
often	O
positive	O
for	O
CU	O
-	O
18	O
(	O
71	O
%	O
)	O
,	O
Leu	O
-	O
M1	O
(	O
75	O
%	O
)	O
,	O
B72	O
.	O
3	O
(	O
50	O
%	O
)	O
,	O
HMFG	O
-	O
2	O
(	O
67	O
%	O
)	O
,	O
Ber	O
-	O
EP4	O
(	O
83	O
%	O
)	O
and	O
mCEA	O
(	O
71	O
%	O
)	O
.	O

Using	O
these	O
antibodies	O
,	O
the	O
frequency	O
of	O
positivity	O
for	O
HCC	B-Cancer
was	O
9	O
%	O
,	O
16	O
%	O
,	O
11	O
%	O
,	O
20	O
%	O
,	O
36	O
%	O
,	O
and	O
11	O
%	O
,	O
respectively	O
.	O

CU	O
-	O
18	O
was	O
the	O
only	O
monoclonal	O
antibody	O
in	O
which	O
there	O
was	O
a	O
significant	O
difference	O
in	O
positive	O
rates	O
between	O
HCC	B-Cancer
and	O
metastatic	B-Cancer
adenocarcinomas	I-Cancer
.	O

Most	O
HCCs	B-Cancer
(	O
71	O
%	O
)	O
revealed	O
a	O
bile	B-Multi-tissue_structure
canalicular	I-Multi-tissue_structure
staining	O
pattern	O
with	O
pCEA	O
.	O

Because	O
this	O
staining	O
pattern	O
was	O
absent	O
in	O
metastatic	B-Cancer
carcinomas	I-Cancer
,	O
pCEA	O
appears	O
to	O
be	O
useful	O
in	O
confirming	O
a	O
diagnosis	O
of	O
HCC	B-Cancer
.	O

AE1	O
,	O
AE3	O
and	O
CAM5	O
.	O
2	O
antibodies	O
were	O
not	O
useful	O
in	O
distinguishing	O
HCC	B-Cancer
from	O
metastatic	B-Cancer
carcinomas	I-Cancer
.	O

Each	O
cholangiocarcinoma	B-Cancer
shared	O
a	O
staining	O
profile	O
similar	O
to	O
that	O
of	O
metastatic	B-Cancer
carcinomas	I-Cancer
.	O

